Blood Products

Company developing synthetic blood substitute selects contract researcher

Published in Hematology Week, June 6th, 2005

Sanguine Corp. (SGNC), a bio-pharmaceutical company focused on developing an oxygen-carrying synthetic substitute for human red blood cells and other areas requiring oxygen profusion, has selected a contract researcher.

Beckloff Associates Inc., a division of Cardinal Health, was chosen by Sanguine as its contract researcher to conduct U.S. Food and Drug Administration (FDA) testing programs for PHER-O2.

The current endeavor includes developing testing projects for a select few indications using the oxygen-carrying attribute of PHER-O2. The analysis is expected to result in selecting a single indication and subsequent testing protocol.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2005-06-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry